Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Tizanidine Hydrochloride,Inapplicable
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Bioequivalence Study of Tizanidine HCl Tablets 4 mg of Dr.Reddys Under Fasting Conditions
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 17, 2010
Lead Product(s) : Tizanidine Hydrochloride,Inapplicable
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tizanidine Hydrochloride,Inapplicable
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Bioequivalence Study of Tizanidine HCl 4mg Tablets of Dr.Reddy's Under Fed Conditions
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 10, 2010
Lead Product(s) : Tizanidine Hydrochloride,Inapplicable
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Etoricoxib,Tizanidine Hydrochloride
Therapeutic Area : Neurology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 07, 2025
Lead Product(s) : Etoricoxib,Tizanidine Hydrochloride
Therapeutic Area : Neurology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Metaxalone,Tizanidine Hydrochloride
Therapeutic Area : Neurology
Study Phase : Phase IV
Sponsor : Sun Valley Arthritis Center
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 24, 2024
Lead Product(s) : Metaxalone,Tizanidine Hydrochloride
Therapeutic Area : Neurology
Highest Development Status : Phase IV
Sponsor : Sun Valley Arthritis Center
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tizanidine Hydrochloride,Inapplicable
Therapeutic Area : Urology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Effect of Tizanidine on Postoperative Urinary Retention After Sacrospinous Suspension
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 14, 2024
Lead Product(s) : Tizanidine Hydrochloride,Inapplicable
Therapeutic Area : Urology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tizanidine Hydrochloride,Inapplicable
Therapeutic Area : Neurology
Study Phase : Phase III
Sponsor : Credit Pharmaceutical
Deal Size : Inapplicable
Deal Type : Inapplicable
TIzanidine for the Preventive Treatment of Episodic MigrainE (TIME)
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 02, 2022
Lead Product(s) : Tizanidine Hydrochloride,Inapplicable
Therapeutic Area : Neurology
Highest Development Status : Phase III
Sponsor : Credit Pharmaceutical
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tizanidine Hydrochloride,Inapplicable
Therapeutic Area : Musculoskeletal
Study Phase : Undisclosed
Sponsor : National Institutes of Health
Deal Size : $2.5 million
Deal Type : Funding
Details : Proceeds from the financing will be used for the advancement of the company’s tizanidine implant product (DLP-208) for moderate-severe spasticity. DLP-208 can provide sustained therapy for several months, while only requiring a 10-minute procedure in a...
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
November 16, 2021
Lead Product(s) : Tizanidine Hydrochloride,Inapplicable
Therapeutic Area : Musculoskeletal
Highest Development Status : Undisclosed
Sponsor : National Institutes of Health
Deal Size : $2.5 million
Deal Type : Funding
Lead Product(s) : Vitamin B1,Pyridoxine Hydrochloride,Vitamin B12,Diclofenac Sodium,Tizanidine Hydrochloride
Therapeutic Area : Neurology
Study Phase : Phase III
Sponsor : Bausch Health
Deal Size : Inapplicable
Deal Type : Inapplicable
Safety and Efficacy of Neuromultivit in Treatment of Vertebrogenic Radiculopathy
Details : Undisclosed
Product Name : Undisclosed
Product Type : Vitamins/Minerals/Inorganic Salts
Upfront Cash : Inapplicable
July 27, 2015
Lead Product(s) : Vitamin B1,Pyridoxine Hydrochloride,Vitamin B12,Diclofenac Sodium,Tizanidine Hydrochloride
Therapeutic Area : Neurology
Highest Development Status : Phase III
Sponsor : Bausch Health
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tizanidine Hydrochloride,Vemurafenib
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 01, 2013
Lead Product(s) : Tizanidine Hydrochloride,Vemurafenib
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tizanidine Hydrochloride,Inapplicable
Therapeutic Area : Musculoskeletal
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 24, 2013
Lead Product(s) : Tizanidine Hydrochloride,Inapplicable
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable